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Abstract: The mitochondrion is vital for many metabolic pathways in the cell, contributing 
all or important constituent enzymes for diverse functions such as β-oxidation of fatty acids, 
the urea cycle, the citric acid cycle, and ATP synthesis. The mitochondrion is also a major 
site  of  reactive  oxygen  species  (ROS)  production  in  the  cell.  Aberrant  production  of 
mitochondrial ROS can have dramatic effects on cellular function, in part, due to oxidative 
modification of key metabolic proteins localized in the mitochondrion. The cell is equipped 
with  myriad  antioxidant  enzyme  systems  to  combat  deleterious  ROS  production  in 
mitochondria, with the mitochondrial antioxidant enzyme manganese superoxide dismutase 
(MnSOD) acting as the chief ROS scavenging enzyme in the cell. Factors that affect the 
expression and/or the activity of MnSOD, resulting in diminished antioxidant capacity of 
the cell, can have extraordinary consequences on the overall health of the cell by altering 
mitochondrial metabolic function, leading to the development and progression of numerous 
diseases. A better understanding of the mechanisms by which MnSOD protects cells from 
the  harmful  effects  of  overproduction  of  ROS,  in  particular,  the  effects  of  ROS  on 
mitochondrial metabolic enzymes, may contribute to the development of novel treatments 
for various diseases in which ROS are an important component. 
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1. Introduction 
Reactive  oxygen  species  (ROS)  are  by-products  of  oxygen  metabolism  [1].  Long  thought  to  
have only deleterious effects on cells (damage to lipids, protein, and DNA), ROS have proven to be 
vital mediators of a host of cellular processes, including cell adhesion, apoptosis, and the immune 
response [2], as well as cell growth and differentiation [3]. ROS are also important second messengers 
in  intracellular  signaling  [4,5].  A  delicate  proportionality  exists  between  ROS  production  and 
obliteration,  and  interruption  of  this  proportionality  leads  to  aberrant  ROS  accumulation,  which 
contributes to the development of myriad diseases, including various neurological disorders [6] and 
cancer [7–9]. 
The mitochondrion is an important metabolic center of the cell. Mitochondria contain many, or all, 
components of such diverse metabolic pathways as heme synthesis [7], β-oxidation of fatty acids [8], 
tricarboxylic acid (TCA) cycle [9], amino acid metabolism [10,11], the urea cycle [12], and oxidative 
phosphorylation to form ATP [13].  
Mitochondria,  the  major  oxygen-metabolizing  organelles  of  the  cell,  are  also  the  major  source  
of  ROS  in  the  cell,  with  the  superoxide  radical  (O2
•−)  as  the  initial  ROS  produced  by  this  
organelle [14,15]. Superoxide radicals can participate in the production of other radicals, including the 
reactive nitrogen species (RNS) peroxynitrite [16]. ROS can alter cellular function by affecting the 
activity  of  myriad  proteins,  including  mitogen-activated  [17,18]  and  serine/threonine  kinases  [19], 
protein tyrosine and serine/threonine phosphatases [20], and multiple transcription factors, including 
AP-1 [21], NF-κB [22], HIF-1 [23], and p53 [24–26]. Metabolic enzymes localized to mitochondria 
are susceptible to attack by ROS due to their proximity to the sites of ROS production. ROS-mediated 
changes  in  the  activities  of  these  metabolic  enzymes  can  have  remarkable  consequences  on  the 
homeostasis  of  the  cell.  This  review  focuses  on  effects  of  ROS  on  key  mitochondrial  enzymes 
involved in different vital metabolic pathways.  
Because  ROS  are  important  for  normal  cellular  activities,  logic  dictates  that  modulation  of  
basal  ROS  concentrations,  either  by  increased  production  of  ROS  from  endogenous  sources, 
exogenous  ROS-generating  agents,  diminished  cellular  antioxidant  capacity,  or  a  combination  of  
the  three,  will  have  a  dramatic  effect  on  cellular  homeostasis  and  may  contribute  to  disease 
development. Manganese superoxide dismutase (MnSOD) is the major ROS detoxifying enzyme of 
cells because of its localization to mitochondria. Altered function or expression of MnSOD can have 
remarkable consequences on mitochondrial function and the overall health of cells due to oxidative 
damage to various mitochondria-localized metabolic processes, leading to the development of different 
diseases [27,28]. This review will focus on important sources of mitochondrial ROS production, the 
role of MnSOD in scavenging mitochondrial ROS, the effects of ROS on different metabolic enzymes, 
and  the  importance  of  MnSOD  in  protecting  mitochondria  from  the  deleterious  effects  of 
mitochondria-derived ROS, with an emphasis on disease development. 
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2. Mitochondrial Production of ROS 
2.1. Mitochondria is a Major Source of ROS 
Mitochondria are the main source of ROS (particularly superoxide radicals) in the cell due, in part, 
to  the  oxygen  metabolism  that  occurs  at  this  organelle  [29,30].  Multiple  enzymes  in  the  electron 
transport chain are responsible for superoxide production [31], with complexes I (NADH-ubiquinone 
oxidoreductase)  [32,33]  and  III  (ubiquinol-cytochrome  c  oxidoreductase)  [34]  as  major  sites  of 
superoxide production. For complex I, the site of superoxide generation was pinpointed to the region 
between the ferricyanide and ubiquinone reduction sites [35] and was further refined to the iron-sulfur 
centers N1a [36] and N2 [37]. The proton-pumping activity of complex I is another vital source of 
superoxide production. The proton pump inhibitor EIPA increases superoxide production at complex I 
considerably and enhances rotenone-mediated superoxide production [38]. Superoxide production at 
complex III involves the ubisemiquinone intermediate of the Q-cycle [34], and superoxide is released 
on  both  sides  of  the  inner  mitochondrial  membrane  [39]  into  both  the  matrix  [40]  and  the 
intermembrane space [41]. 
Complex II also adds to the total amount of superoxide radicals produced by mitochondria. The  
site  of  superoxide  production  at  complex  II  was  suggested  to  be  distal  to  the  site  of  succinate  
oxidation [42], and was identified as either the reduced cytochrome b566 or ubisemiquinone of the of 
the Q0 site of the cytochrome bc1 complex of Complex II [43]. 
Other enzymes within the mitochondria not directly tied to the electron transport chain are also 
sources of mitochondrial ROS. α-ketoglutarate dehydrogenase (α-KGDH), an important component of 
the citric acid cycle, contributes to ROS formation in a way that is dependent on the NADH/NAD
+ 
ratio [44], with the dihydrolipoyl dehydrogenase component of α-KGDH as the major site of ROS 
production  [45].  Dihydroorotic  dehydrogenase  (a  component  of  pyrimidine  synthesis)  produces 
superoxide  as  a  byproduct  of  oxidizing  dihydroorotate  to  orotate  [46,47].  Glycerophosphate 
dehydrogenase  [48,49]  and  cytochrome  P450s  [50,51]  also  contribute  to  total  ROS  production  
by mitochondria. 
Superoxide radicals contribute to the production of other reactive oxygen species that further damage 
mitochondria. Mitochondria possess many proteins with iron-sulfur centers that are susceptible to attack 
by  superoxide,  resulting  in  the  release  of  free  iron  cations  into  the  mitochondria.  Iron  cations 
participate in the production of hydroxyl radicals from hydrogen peroxide through the Haber-Weiss 
reaction  [52–55].  Superoxide  radicals  also  react  with  mitochondrial  nitric  oxide  to  produce 
peroxynitrite, a reactive nitrogen species (RNS) [56]. Peroxynitrite can modify various amino acids in 
proteins,  including  oxidation  of  sulfhydryl  groups  on  proteins  [57]  and  the  nitration  of  tyrosine 
residues  [58].  Mitochondrial  enzymes  are  no  exception  to  attack  by  peroxynitrite  [59],  with  such 
diverse targets as electron transport chain components complex I [60–63], complex II [61,63], and 
complex V [61], as well as glutathione peroxidase [64], aconitase [65,66], and MnSOD. 
2.2. Ways to Scavenge Mitochondrial ROS 
Because of the deleterious effects of ROS, the cell is equipped with several enzyme systems to 
detoxify  ROS  produced  throughout  the  cell  [67,68].  Superoxide  dismutases  are  the  major  ROS Int. J. Mol. Sci. 2011, 12                       
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detoxifying  enzymes  of  the  cell  [69]  and  catalyze  the  dismutation  of  superoxide  radicals  to  
hydrogen peroxide and molecular oxygen [70]. Glutathione peroxidase [71,72], peroxiredoxins [73], 
and catalase [74] decompose hydrogen peroxide generated by SODs to water. Three types of SOD are 
expressed by cells, encoded by separate genes (reviewed in [75]). Copper- and zinc-containing SOD 
(CuZnSOD, SOD1) is a homodimer primarily localized to the cytoplasm [76], though, small amounts 
of CuZnSOD have been identified in the intermembrane space of mitochondria [77,78]. Extracellular 
SOD (ECSOD, SOD3) shares significant amino acid homology with CuZnSOD (40–60%), contains 
both copper and zinc in its active site, but is localized to the extracellular region of the cell [79,80]. 
MnSOD  is  a  homotetramer  [81–83]  localized  exclusively  in  the  mitochondrial  matrix  [77,78]  
and  is  found  in  multiple  organisms,  including  Saccharomyces  cerevisiae  [82],  the  red  alga  
Porphyridium cruentum [84], Escherichia coli B [85], and chicken liver mitochondria [78]. 
Hydrogen peroxide, while not a radical, is also a ROS, and the cell has developed many enzyme 
systems to catalyze the decomposition of hydrogen peroxide to water and molecular oxygen [67].  
Two forms of peroxiredoxin (PRX) exist in mitochondria [73]: PRX III [86,87] and PRX V [88]. 
Thioredoxin is used by peroxiredoxins to decompose hydrogen peroxide, generating water and oxidized 
thioredoxin in the process. Reduced thioredoxin is regenerated by thioredoxin reductase II [89,90]. 
Glutathione  peroxidase  (GPX)  is  another  enzyme  that  removes  hydrogen  peroxide  from  the  cell.  
GPX1 [71] and phospholipid-hydroperoxide GPX [72] (PHGPX) are the two mitochondrial forms of 
GPX, with GPX1 localized to the matrix and PHGPX embedded in the inner membrane [91]. GPX 
uses glutathione (GSH) to reduce hydrogen peroxide to water, generating oxidized glutathione (GSSG) 
in the process. GSH is regenerated from GSSG by the enzyme glutathione reductase [92]. Catalase also 
scavenges  hydrogen  peroxide  in  the  cell  [93,94],  however,  controversy  exists  concerning  the 
localization of catalase in the cell. Some labs report catalase in the nucleus, peroxisomes, and the 
sarcoplasm, but not mitochondria, in mice overexpressing catalase [95]. Other labs have discovered 
catalase not only in mitochondria [96], but in the matrix of mitochondria [97].  
3. MnSOD is Essential for Aerobic Life 
Numerous studies in different model systems demonstrate the indispensable role for MnSOD in 
protecting aerobic life from the deleterious effects of oxygen. Gregory and Fridovich [98] discovered 
that E. coli B cells grown under 100% oxygen were more resistant to hyperbaric concentrations of 
oxygen (20 atm) than Bacillus subtilis or cells grown under normal atmospheric conditions due to 
oxygen-stimulated  expression  of  MnSOD.  These  E.  coli  B  cells  were  also  more  resilient  against 
exposure to the superoxide-generating antibiotic streptonigrin. Similar results were seen with the yeast 
strain Saccharomyces cerevisiae var. ellipsoideus [99]. 
Complete knockout of MnSOD has no effect on embryonic development, but leads to death shortly 
after birth. Depletion of MnSOD enzymatic activity by expression of inactive mutants or knockout of 
MnSOD gene expression causes early death in mouse [100] and Drosophila models [101] due, in part, 
to  decreased  activity  of  various  mitochondrial  proteins  [100,102]  (see  Effects  of  MnSOD  on 
Mitochondrial Integrity/Function below). In a study using heterozygous MnSOD knock-out mice (with 
a 50% reduction in MnSOD enzyme activity in all tissues) [103], there is an increase in oxidative DNA 
damage  (as  measured  by  formation  of  8-oxodeoxyguanidine)  in  nuclear  and  mitochondrial  DNA Int. J. Mol. Sci. 2011, 12                       
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compared to wild-type mice. This increase in oxidative DNA damage was age-dependent, however, 
other markers of aging (cataract formation, immune response, etc.) were not affected. Interestingly, a 
100% increase in cancer incidence was observed in MnSOD heterozygous knockout mice compared to 
wild-type  controls.  In  a  study  by  Copin  et  al.  [104],  mice  were  generated  that  simultaneously 
overexpressed  CuZnSOD  and  were  deficient  in  MnSOD.  Overexpression  of  CuZnSOD  did  not 
compensate  for  the  neonatal  lethality  caused  by  decreased  MnSOD  expression,  suggesting  that 
localization of the antioxidant enzymes is vital to oxidative-stress related cellular damage. In a recent 
study  in  Drosophila,  Mukherjee  et  al.  found  that  while  MnSOD  is  essential  for  the  viability  of  
adult  flies,  the  lack  of  MnSOD  has  no  effect  on  embryogenesis  or  later  development  and 
differentiation [105], which seems to be consistent with mouse models, in which homozygous MnSOD 
knockout  mice  are  of  normal  size  and  have  no  detectable  gross  deformities  at  birth  [100].  The 
increased death rate observed in MnSOD homozygous knockout neonates compared to heterozygous 
knockouts and wildtype littermates may be due to the inability to these animals to compensate for 
exposure to higher oxygen levels in the atmosphere compared to oxygen levels experienced in the 
uterus. Various anatomical abnormalities contribute to early death observed in MnSOD knockout mice. 
Li  et  al.  generated  a  strain  of  mice  expressing  an  enzymatically  inactive  mutant  of  MnSOD  and 
identified several cardiovascular abnormalities in homozygous MnSOD knock-out animals, including 
dilated  left  ventricular  cavity,  reduced  left  ventricular  wall  thickness,  and  myocardial  hypertrophy 
resulting in dilated cardiomyopathy [100]. Lebovitz et al. [106] generated a line of MnSOD knockout 
mice (SOD2
m1BCM/SOD2
m1BCM) by deleting exons 1 and 2 from the MnSOD gene. These mice live up 
to three weeks after birth, but suffer from severe anemia due to lower levels of all hematopoietic cells, 
resulting in hypocellular bone marrow. Cardiac injury is also observed in the SOD2
m1BCM/SOD2
m1BCM 
mice, with approximately 10% of the animals demonstrating cardiac injury due to balloon-like cardiac 
dilation and ventricular wall thinning.  
Conditional knockout of MnSOD using the Cre-Lox system has proven valuable in determining the 
tissue-specific effects of reduced MnSOD. Ikegami et al. developed a MnSOD flox mouse, and used 
this mouse to develop a liver-specific MnSOD knockout model. The researchers found that knockout 
of MnSOD in the liver had no effect on morphology and there was no increase in oxidative damage as 
determined by lipid peroxidation, suggesting that either the liver contains compensatory mechanisms 
to  protect  from  oxidative  stress  or  the  liver  is  susceptible  to  systemic  oxidative  stress  [107].  
Kidney-specific knockout of MnSOD has no effect on lifespan, but does result in a decrease in body 
weight  compared  to  Cre  control  mice.  Interestingly,  while  MnSOD  knockout  mice  exhibit  altered 
kidney morphology and increased tyrosine nitration of kidney proteins, there was no overall renal 
dysfunction compared to Cre control mice [108]. Specific knockdown of MnSOD in type IIB skeletal 
muscle in C57/BL6 mice results in a significant elevation in mitochondrial superoxide production, 
causing  an  increase  in  oxidative  damage.  This  damage  leads  to  a  decrease  in  the  ability  of  the 
gastrocnemius and extensor digitorum longus muscles to produce force over time, as well as decreases 
the  aerobic  exercise  capacity  in  these  mice  compared  to  controls  [109].  Interestingly,  MnSOD 
knockdown  in  type  IIB  skeletal  muscle  does  not  affect  age-dependent  muscle  atrophy  [110]. 
Conditional  knockout  of  MnSOD  in  postnatal  neurons  does  not  result  in  an  increase  in  oxidative 
damage, even one year after birth, but does lead to an increase in disorganization of distal nerve axons 
after injury [111]. Int. J. Mol. Sci. 2011, 12                       
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Logic suggests that if a decrease in MnSOD has deleterious effects, then overexpression of MnSOD 
may be beneficial. In a study by Jang et al. [112], the effects of MnSOD overexpression on age-related 
biomarkers was investigated. While overexpression of MnSOD causes an increase in aconitase activity, 
a decrease in age-related decline in mitochondrial ATP production, a decrease in lipid peroxidation, 
and protected the mice from paraquat-induced oxidative stress, there were no statistically significant 
differences between wild-type and MnSOD-overexpressing mice with respect to lifespan or age-related 
pathology. Likewise, overexpression of the antioxidant enzymes CuZnSOD, catalase, or a combination 
of CuZnSOD with either catalase or MnSOD does not increase the life span of mice [113]. On the other 
hand, induction of MnSOD expression in Drosophila melanogaster caused an increase in the mean life 
span of the animals without affecting overall oxygen consumption [114]. 
4. Effects of MnSOD on Mitochondrial Integrity/Function 
4.1. Electron Transport Chain 
Complexes I, II, and III are sources of superoxide (see Mitochondria are a Major Source of ROS, 
above) and potential victims of the very superoxide they produce, in part, due to the presence of  
iron-sulfur  centers  in  key  subunits  of  all  three  complexes  [115–120].  These  complexes  are  also 
susceptible to oxidative modification of key amino acids by superoxide and other ROS/RNS, which 
can affect their activities. For example, in a study by Chen et al. on the complex I subunit NADH 
dehydrogenase,  Cys206  and  Tyr177  were  two  amino  acids  susceptible  to  oxidative  modification, 
causing a decrease in the electron transport function of complex I [121], and this type of auto-oxidation 
of complex I may be involved in Parkinson’s disease [122]. Complex I [123–126] and complex III [126] 
are also vulnerable to inactivation by peroxynitrite, the product of the reaction of superoxide and nitric 
oxide. Inactivation of electron transport complexes by ROS/RNS may be involved in such diverse 
pathological conditions as cellular damage associated with ionizing radiation [126] or the development 
and progression of various neurological disorders [122,123,125]. 
MnSOD is important for the scavenging of superoxide generated by the electron transport chain 
complexes  and  may  be  important  in  preventing  ROS-induced  inactivation  of  these  complexes. 
Knockdown of MnSOD in myriad model systems demonstrate altered activity of complexes I, II, and 
III. Complete knockout of MnSOD in mice causes a substantial reduction in succinate dehydrogenase 
(complex  II)  levels  in  heart  tissue  [100].  Williams  et  al.  show  that  mitochondria  isolated  from 
heterozygous MnSOD knockout mice (MnSOD
−/+) have a decrease in the respiratory control ratio 
(RCR) compared to wildtype mice (MnSOD
+/+). The decrease in RCR was greatest for the complex I 
substrate glutamate/malate and the complex III substrate duroquinol, and the diminished RCR was 
linked  to  a  decrease  in  state  III  respiration.  The  authors  found  a  decrease  in  complex  I  activity  
in MnSOD
−/+ mice compared to MnSOD
+/+, and this decreased activity was due to oxidation of the 
iron-sulfur center of complex I [127]. Using wildtype and MnSOD
−/− mouse erythroblasts, Martin et al. 
identified by microarray several nuclear  gene-encoded subunits of all five complexes of oxidative 
phosphorylation  that  were  all  downregulated  in  MnSOD
−/−  erythroblasts  compared  to  wildtype  
cells [128]. Larosche et al. used mice that were either heterozygous MnSOD knockout (MnSOD
+/−), 
wildtype for MnSOD, or overexpressing mouse MnSOD (MnSOD
+++) to better understand the role of Int. J. Mol. Sci. 2011, 12                       
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MnSOD  in  the  effects  of  acute  ethanol  exposure.  The  researchers  found  that  in  wildtype  and 
MnSOD
+/− mice, there was a significant decrease in the activities of both complex I and complex V, 
while these effects of ethanol were completely blocked in MnSOD
+++ mice. Ethanol administration 
also resulted in an increase in iNOS expression in all three genotypes, but nitration of complexes I and V 
was only observed in MnSOD
+/− mice. These results demonstrate an important role for MnSOD in 
modulating  peroxynitrite  formation,  and  subsequent  nitration  of  susceptible  proteins,  in  part,  by 
removing excess superoxide that may contribute to peroxynitrite formation [129].  
This  laboratory  has  conducted  much  work  concerning  the  off-target  effects  of  the  cancer 
chemotherapeutic drug adriamycin, especially cardiac and neurological toxicities. A major side effect 
of  anthracycline  chemotherapy  in  cancer  patients,  especially  adriamycin,  is  a  dose-dependent 
cardiotoxicity [130] that eventually leads to dilated cardiomyopathy and congestive heart failure [131]. 
The mitochondrion is an important target of adriamycin [132], and because excessive ROS production is 
a mechanism of adriamycin-induced cardiotoxicity, alterations in the capacity of cells to scavenge ROS 
can impact the cardiac injury caused by adriamycin [133–135]. Using transgenic mice overexpressing 
various amounts of MnSOD, this laboratory was the first to demonstrate that mitochondrial ROS is vital 
for adriamycin-induced cardiac injury [136]. In non-transgenic animals, adriamycin causes a significant 
reduction  in  the  respiratory  control  ratio  and  state  III  respiration  at  complexes  I  and  II.  In  mice 
overexpressing MnSOD, only complex II activity is affected, implying that MnSOD protects complex I 
from deactivation caused by adriamycin-induced superoxide production [137].  
Another potential side effect of cancer chemotherapy is cognitive decline characterized by memory 
loss,  decreased  reaction  time,  and  diminished  concentration  [138,139],  sometimes  referred  to  
by patients as chemobrain [140,141]. Adriamycin can cause changes to both the structure [142,143] 
and activity [144] of various regions of the brain, and oxidative stress is thought to be an important 
mechanism of cognitive dysfunction associated  with chemotherapy [145,146]. This laboratory  was  
the first to demonstrate a unique mechanism of adriamycin-induced neurotoxicity. Adriamycin does 
not cross the blood brain barrier [147], but it does cause a substantial increase in levels of TNF-α in 
serum,  whole  brain  homogenate,  and  increased  TNF-α  staining  in  the  hippocampus  and  cortex  of 
mouse brain. Like the effects observed in cardiac tissue, adriamycin causes a significant reduction in 
state  III  respiration  due  to  decreased  complex  I  activity  [148].  Another  important  mechanism  of 
adriamycin-induced neurotoxicity is modulation of MnSOD enzyme activity. Adriamycin treatment 
leads to increased nitration of MnSOD and a corresponding decrease in MnSOD enzyme activity. The 
effects of adriamycin on MnSOD were not observed in iNOS knock-out mice, implying both a role for 
iNOS in adriamycin-induced neurotoxicity and the importance of MnSOD in preventing this type of 
chemotherapy-mediated injury [145].  
4.2. Tricarboxylic Acid (TCA) Cycle 
The TCA cycle (also known as the Krebs cycle) is a vital metabolic pathway in mitochondria, 
providing reducing equivalents that are fed into the electron transport chain for ATP production and 
generating substrates used in a variety of cellular processes. Altered activity of various enzymes in the 
TCA cycle has been linked to different neurological diseases and cancer [9,149].  Int. J. Mol. Sci. 2011, 12                       
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Aconitase,  the  enzyme  that  catalyzes  the  conversion  of  aconitate  to  isocitrate  [9],  contains  
iron-sulfur centers and is susceptible to deactivation by superoxide [65,150,151] leading to release of 
Fe(II)  from  the  enzyme  (reviewed  in  [152]).  Aconitase  is  also  sensitive  to  inactivation  by  other 
ROS/RNS, such as S-nitrosoglutathione [153] and peroxynitrite [66,153,154]. Peroxynitrite inactivates 
aconitase  by  attacking  two  sites  within  the  enzyme.  Low  levels  of  peroxynitrite  inhibit  aconitase 
activity, in the absence of citrate, by attacking the iron-sulfur center, converting the [4Fe-4S] center to a 
[3Fe-4S], with a loss of iron. Much higher concentrations of peroxynitrite are required for inactivation 
when aconitase is in the presence of citrate. The mechanism of inactivation in this case is oxidation of 
cysteine 385, which binds to the iron-sulfur center, to sulfonic acid, as well as nitration of key tyrosines 
and oxidation of cysteine residues to sulfonic acid near the active site of the enzyme [154].  
Several studies in various models demonstrate the importance of MnSOD in maintaining aconitase 
activity,  including  Arabidopsis  thaliana  [155],  yeast  [156],  Drosophila  [101]  ,  and  mouse  [127].  
For example, microarray analysis of normal and MnSOD
−/− mouse erythroids found that complete 
knockout  of  MnSOD  leads  to  a  significant  decrease  in  the  expression  of  nearly  all  enzymes  and 
regulatory proteins involved in the TCA cycle [128]. In liver mitochondria from MnSOD
+/− mice, 
aconitase activity was significantly reduced and was rescued by addition of iron and dithiothreitol, 
indicating  that  inactivation  of  aconitase  may  be  due  to  oxidation  of  the  protein  by  superoxide  
radicals  [127].  In  A549  human  lung  adenocarcinoma  cells,  overexpression  of  MnSOD  prevented 
inactivation  of  aconitase  induced  by  hypoxia-reoxygenation  of  the  cells  [157],  as  well  as  the  
redox-cycling agent phenazine methosulfate and electron transport chain inhibitors [150]. 
4.3. Iron Metabolism 
The mitochondrion is vital for proper iron handling and utilization [158] and is the site of two 
important  iron-consuming  processes:  the  synthesis  of  iron-sulfur  centers  [159]  and  heme  [7]. 
Mitochondria  are  also  important  for  intracellular  iron  storage  by  virtue  of  the  presence  of  a 
mitochondria-specific ferritin (reviewed in [160]). Improper sequestration and use of iron can lead to 
iron-induced  oxidative  damage  [161]  and  is  associated  with  several  disorders,  including  X-linked 
sideroblastic anemia, Friedreich ataxia, hereditary myopathy, and X-linked sideroblastic anemia with 
ataxia [162,163]. 
Altered expression or mutations of MnSOD can have dramatic effects on cellular iron handling. 
Using  electron paramagnetic resonance (EPR),  Srinivassan et al. demonstrated that knockdown of 
CuZnSOD, MnSOD, or both in yeast results in a dramatic increase in the amount of EPR-detectable 
iron compared to wild-type yeast [164]. The Ala16Val polymorphism of the Sod2 gene (rs4880) is a 
common single nucleotide polymorphism, and the Ala-MnSOD variant is associated with an increase 
in  intracellular  iron  in  patients  with  alcohol-induced  liver  cirrhosis  and  an  increased  risk  of 
hepatocellular carcinoma. Transfection of the Ala-MnSOD into the Huh7 human hepatoma cell line 
increases the expression of cytosolic ferritin, transferrin receptors-1 and -2, hepcidin, and frataxin, 
proteins involved in different aspects of iron handling [165]. Complete knockout of MnSOD in mouse 
erythroblasts causes a significant increase in transferrin mRNA [128]. 
The  ATP  binding  cassette  subfamily  B  member-7  (ABCb7)  is  another  iron-processing  
protein  affected  by  MnSOD.  ABCb7  is  a  transporter  protein  localized  to  the  inner  mitochondrial Int. J. Mol. Sci. 2011, 12                       
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membrane [166], is important for export of iron-sulfur centers from mitochondria to the cytosol, and is 
essential for the formation of cytosolic iron-sulfur center-containing proteins [167,168]. Mutations or 
loss  of  ABCb7  are  linked  to  sideroblastic  anemia  with  ataxia  [168–170]  and  mitochondrial 
accumulation of iron [170–172]. Knockout of MnSOD in erythroid cells is associated with a decrease 
in the expression of ABCb7 [128]. These studies suggest that decreased MnSOD expression or activity 
causes accumulation of iron in cells, specifically within mitochondria. Increased MnSOD expression 
or activity may prove valuable for the treatment of iron toxicity caused by numerous diseases. 
Changes in iron metabolism can affect MnSOD expression. Work by Pinkham et al. identified 
SOD2 as a heme-responsive gene, and heme-dependent regulation occurs through the presence of three 
cis  elements  involved  that  are  bound  by  Hap1p,  a  heme-binding  transcription  factor  [173].  Heme 
oxygenase-1 (HO-1) is an enzyme involved in the rate-limiting step of heme degradation: the cleavage 
of the meso carbon bridge of heme to form biliverdin-IX, carbon monoxide, and free iron. HO-1 is 
found in mitochondria, where it regulates mitochondrial heme content and the expression of several 
genes,  including  cytochrome  c  oxidase  subunit  I  and  mitochondrial  nitric  oxide  synthase  [174]. 
Transfection  of  cultured  rat  astroglial  cells  with  HO-1  induces  MnSOD  expression,  which  was 
attenuated by treatment with various antioxidants, suggesting a role for oxidative stress in MnSOD 
expression  stimulated  by  HO-1  [175].  Jiralerspong  et  al.  found  that  in  primary  fibroblasts,  
iron-induced  expression  of  MnSOD  is  impaired  in  fibroblasts  isolated  from  Friedreich  ataxia  
patients compared to fibroblasts isolated from normal patients. Only high levels of iron could induce 
MnSOD  expression  in  the  Friedreich  ataxia  fibroblasts,  and  this  induction  occurs  through  an  
NF-κB-independent  mechanism.  [176]  These  studies  imply  that  iron  metabolism  and  MnSOD 
expression are tightly regulated, that a feedback mechanism is present in cells to carefully balance iron 
metabolism and oxidative stress, and diseases can result from an upset of this balance.  
4.4. Apoptosis 
Apoptosis is a tightly regulated type of cell death that targets single cells or small groups of cells. 
Cells first undergo condensation of the cytoplasm and nucleus, leading to the formation of apoptotic 
bodies, small membrane-bound fragments containing cellular components. Healthy cells surrounding 
the  apoptotic  cell  then  phagocytose  the  apoptotic  bodies  [177,178].  Apoptosis  is  important  for  a 
multitude of cellular processes, including the immune response and embryonic development [179]. 
Apoptosis occurs by two different pathways: extrinsic and intrinsic. During extrinsic apoptosis, the cell 
receives an  external stimulus for cell death [180], while some internal stress triggers the intrinsic 
pathway of apoptosis [181,182].  
Mitochondria are important sites for the initiation and progression of apoptosis [183,184]. Changes 
in  mitochondrial  membrane  potential,  permeabilization  of  the  mitochondrial  membrane,  and  ROS 
generation  can  all  trigger  apoptosis  [185].  Upon  mitochondrial  dysfunction,  many  molecules  are 
released from mitochondria to initiate and propagate apoptosis. Cytochrome c, when released into the 
cytoplasm, interacts with Apaf-1 to form a protein complex called the apoptosome, which promotes 
activation of caspase 9. Omi/Htr2 and Smac/Diablo interfere with various members of the inhibitor of 
apoptosis (IAP) family. Apoptosis inducing factor (AIF) and endonuclease G translocate to the nucleus 
and participate in DNA degradation [186]. Int. J. Mol. Sci. 2011, 12                       
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Several  mechanisms  have  been  implicated  in  MnSOD  protection  from  apoptosis.  MnSOD 
overexpression protects from mitochondrial dysfunction and loss of mitochondrial membrane potential 
caused by various agents that induce apoptosis, including ionizing radiation [187], as well as Fe(II), 
amyloid β-peptide, NO generating agents [188], and tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) [189]. MnSOD also prevents the release of various proteins from mitochondria that 
carry out apoptosis, such as cytochrome c [187] and Smac/DIABLO [189]. 
Modulation  of  ROS  levels,  and  corresponding  ROS-mediated  damage,  is  another  mechanism  of 
MnSOD suppression of apoptosis. Overexpression of MnSOD protects FsaII murine fibrosarcoma cells 
from apoptosis caused by electron transport inhibitors antimycin and rotenone by inhibiting caspase 3 
activity and poly(ADP-ribose) polymerase cleavage, in part, by altering mitochondrial ROS levels [190]. 
In a study by Keller et al. [188], overexpression of MnSOD protects PC6 pheochromocytoma cells from 
apoptosis induced by Fe(II), amyloid β-peptide, and NO generating agents by inhibiting peroxynitrite 
production  and  lipid  peroxidation,  as  well  as  prevents  mitochondrial  transmembrane  potential  
collapse and a decrease in mitochondrial activity caused by these agents. MnSOD also protects against 
apoptosis induced by ionizing radiation and exposure to different anticancer agents [191]. 
MnSOD  also  affects  apoptosis  stimulated  by  inflammatory  cytokines.  Hirose  et  al.  found  that  
in  A375  human  melanoma  cells  and  Chinese  hamster  ovary  cells,  overexpression  of  MnSOD  
protects cells from the toxic effects of inflammatory cytokines [191]. Tumor necrosis factor (TNF) 
induces apoptosis, in part, by stimulating mitochondrial ROS production [192]. MnSOD expression  
is stimulated by TNF and may act as an adaptive response to protect cells from further exposure to 
TNF [193]. As a demonstration of this concept, overexpression of MnSOD confers protection of a 
variety of cell lines against apoptosis induced by tumor necrosis factor (TNF) [194]. This adaptive 
response may protect cells from apoptosis caused by other toxic agents. Pretreatment of hippocampal 
cells with TNF-α protects the cells from apoptosis induced by Fe(II) and amyloid β-peptide, in part, by 
stimulating  MnSOD  expression  [195].  Work  by  this  laboratory  demonstrated  that  tamoxifen,  the 
antiestrogen used to treat breast cancer, enhances TNF-α-induced expression of MnSOD by increasing 
the binding of the p50/p65 heterodimer of NF-κB to an enhancer in the second intron of the MnSOD 
gene [196]. Further work showed that stimulation of MnSOD expression is part of the mechanism of 
tamoxifen-mediated protection from adriamycin-induced apoptosis in cardiac tissue [197]. Pardo et al. 
found  that  in  human  Jurkat  T  cells,  caspase-dependent  degradation  of  MnSOD  is  important  for  
Fas  receptor-mediated  apoptosis,  resulting  in  an  increase  in  superoxide  production  and  enhanced 
apoptosis [198]. A mechanism of MnSOD-induced resistance to TNF-α is thought to be an increase in 
the steady-state levels of hydrogen peroxide [199]. 
4.5. Mitochondrial Control of Innate and Adaptive Immunity 
Innate immunity is the first line of defense for cells against the onslaught of foreign microbes  
or cellular damage. Innate immunity is carried out by a series of pattern recognition receptors (PRRs) 
that recognize key components of microbial invaders referred to as pathogen-associated molecular 
patterns (PAMPs) or various endogenous cellular components that mark cells as damaged or injured 
known as danger-associated molecular patterns (DAMPs). The PRRs can be membrane bound, such as 
the Toll-like receptors found at the membranes of endosomes, lysosomes, or the cell surface. PRRs can Int. J. Mol. Sci. 2011, 12                       
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also  be  cytosolic,  such  as  the  nucleotide-binding  oligomerization  domain  (NOD)-like  receptors  
(NLRs) and the retinoic acid-inducible gene-1 (RIG-1)-like receptors (RLRs) [200–202]. Activation of 
PRRs leads to activation of several transcription factors (NF-κB, AP-1, interferon-regulatory factor 
(IRF)) [202]. PRR activation can also cause formation of inflammasomes, multiprotein complexes 
consisting  of  a  sensing  protein  (NLR),  an  adaptor  protein  (apoptosis-associated  speck-like  protein 
containing a CARD (ASC)), and a caspase, such as caspase 1 [203]. The inflammasome is a platform 
for  activation  of  various  inflammatory  cytokines,  including  interleukin-(IL)  1β,  in  response  to  the 
presence of PAMPs or DAMPs [202]. 
Mitochondria  are  important  for  the  initiation  of  immune  responses.  Seth  et  al.  identified  a 
mitochondrial  antiviral  signaling  (MAVS)  protein  important  for  NF-κB  and  IRF-3-dependent 
expression of interferon-β (IFN-β) in response to viral infection. Silencing MAVS expression by RNAi 
or  overexpression  of  MAVS  abolishes  or  enhances  IFN-β  expression,  respectively.  Mitochondrial 
localization  of  MAVS  is  essential  for  its  function,  since  localization  of  MAVS  to  either  the 
endoplasmic  reticulum  or  plasma  membrane  greatly  reduces  the  ability  of  MAVS  to  induce  
IFN-β expression [204]. Zhan et al. discovered that injury-induced release of mitochondrial DNA or 
formyl peptides activates polymorphonuclear neutrophils and can lead to neutrophil-mediated organ 
injury [205]. Mitochondrial DNA is also important for activation of innate immunity.  In J774A.1 
macrophages, treatment with ethidium bromide to deplete the cells of mitochondrial DNA (ρ
0 cells) 
inhibits  LPS-  and  ATP-induced  caspase-1  activation  and  IL-1β  secretion.  Cytosolic  release  of 
mitochondrial DNA is also important for inflammasome activation, as treatment with DNase I inhibits 
LPS- and ATP-induced activation of the inflammasome, while transfection with mtDNA enhances this 
effect in bone marrow-derived macrophages [206]. 
ROS  are  vital  for  inflammasome  activation  (reviewed  in  [207]).  Dostert  et  al.  found  that  
NADPH  oxidase  (Nox)-generated  ROS  are  involved  in  asbestos-induced  Nalp3  inflammasome 
activation  and  subsequent  interleukin-1β  (IL-1β)  secretion  in  human  macrophages.  Inhibition  of  
Nox  activity  using  diphenylene  iodonium  chloride  or  apocynin  or  scavenging  of  ROS  using  
N-acetylcysteine or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC) hinders asbestos-induced 
IL-1β activation [208]. Later work by Meissner et al. revealed that caspase-1 activation and production 
of IL-1β occurs in mononuclear phagocytes that lack active Nox [209], suggesting other sources of 
ROS may be involved in inflammasome activation. 
Recent  work  by  two  laboratories  has  revealed  that  mitochondria  are  the  major  source  of  ROS 
involved in the activation of inflammasomes. Using the THP1 macrophage cell line, Zhou et al. found 
that chemical inhibition of various components of the electron transport chain increases mitochondrial 
ROS formation and correlates with an increase in activated IL-1β. Inflammasome components NLRP3 
and ASC localize to endoplasmic reticulum and mitochondria in response to inflammasome-stimulating 
agents MSU, alum, and nigericin. The authors demonstrate the importance of VDAC in mitochondrial 
ROS-dependent  inflammasome  formation.  Knockdown  of  VDAC1  and  VDAC2  expression  or 
overexpression of Bcl-2 (which inhibits VDAC function) inhibit caspase-1 activation and formation of 
mature  IL-1β  [210].  In  LPS  or  ATP-stimulated  macrophages,  treatment  with  rotenone  increases 
caspase-1 activation and IL-1β secretion, which is abolished with the antioxidant Mito-TEMPO [206].  
Mitochondrial  ROS  can  also  activate  proinflammatory  cytokines  independent  of  inflammasome 
formation. Bulua et al., using mouse embryonic fibroblasts expressing different mutations of the type 1 Int. J. Mol. Sci. 2011, 12                       
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TNF receptor (TNFR1) associated with the autoinflammatory disorder tumor necrosis factor receptor-
associated periodic syndrome (TRAPS), found that TNFR1 mutant cells have elevated basal levels of 
mitochondrial  ROS,  and  this  mitochondrial  ROS  is  important  for  lipopolysaccharide-stimulated 
production  of  the  proinflammatory  cytokines  IL-6  and  TNF,  but  not  IL-1β,  in  the  absence  of 
inflammasome  formation.  Scavenging  of  mitochondrial  ROS  inhibited  LPS-dependent  cytokine 
production [211]. 
Zhou et al. and Nakahira et al. also link autophagy with inflammasome activation. Inhibition of 
autophagy using the chemical inhibitor 3-methyladenine (3-MA) [210] or knockdown of LC3 [206] or 
beclin-1  [206,210]  causes  increased  mitochondrial  ROS  formation  and  a  corresponding  increase  
in  caspase-1  activation  and  IL-1β  secretion.  Inhibition  of  autophagy  also  prevents  LPS  and  
ATP-stimulation  of  mtDNA  release  into  the  cytosol,  correlating  with  a  decrease  in  caspase-1  
activation  [206].  The  results  of  these  studies  suggest  a  role  for  autophagy  for  the  removal  of  
damaged  mitochondria,  which  prevents  the  activation  of  innate  immunity  through  inflammasome 
formation. When autophagy is inhibited, damaged mitochondria accumulate, resulting in increased 
basal  levels  of  mitochondrial  ROS  and  increased  inflammasome  formation.  These  studies  also  
suggest  exciting  possibilities  for  mitochondrial  antioxidant  enzymes,  particularly  MnSOD,  in  the 
regulation  of  innate  immunity  and  inflammatory  diseases  through  both  inflammasome-dependent  
and -independent mechanisms. 
ROS  production  is  also  vital  for  adaptive  immunity  and  can  affect  T  cell  function.  ROS  are 
important for T cell activation by promoting lipid raft formation for assembly of the T cell activation 
complex [212]. Moulian et al. report that peroxynitrite formation in the thymus is associated with 
apoptosis in human thymocytes [213]. Glutathione depletion is an important mechanism for activated 
T cell death induced by the tryptophan metabolite 3-hydroxyanthranilic acid [214]. ROS are essential 
for hematopoietic progenitor cell differentiation in Drosophila [215]. However, little is known of the 
role  of  MnSOD  in  adaptive  immunity.  Using  a  thymus-specific  MnSOD  knockout  mouse  model,  
Case et al. [216] demonstrated that elevation of superoxide negatively impacts T-cell development and 
alters  adaptive  immune  system  function  by  increasing  apoptosis  and  developmental  defects  in  the  
T-cell  population.  Thymus-specific  knockout  of  MnSOD  leads  to  increased  immunodeficiency  
and  greater  susceptibility  to  influenza  A  H1N1  infection  compared  to  control  mice,  which  were 
rescued  by  treatment  with  superoxide  scavengers  Tempol  or  CTPO.  These  results  reveal  the 
importance of MnSOD in maintaining adaptive immune response and may lead to therapies for various 
immunological disorders involving T-cell dysfunction. 
4.6. Mitochondrial DNA (mtDNA) Stability 
mtDNA is a circular double-stranded DNA molecule that is 16,569 bp long and encodes 37 genes. 
These genes encode for 22 tRNAs and 2 rRNAs that are essential for translation of the remaining  
13 genes, which comprise various components of the electron transport chain [217]. The remainder of 
proteins found in mitochondria are encoded by nuclear DNA, synthesized in the cytosol, and imported 
in mitochondria. mtDNA is organized into discrete foci called nucleoids containing 6–10 individual 
mtDNA genomes each [218,219]. Nucleoids also contain a number of proteins important for synthesis 
and transcription of mtDNA, including mitochondrial single-strand DNA binding protein (mtSSB), Int. J. Mol. Sci. 2011, 12                       
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mitochondrial transcription factor A, and mitochondrial DNA polymerase gamma (Polγ) [219–221]. 
Mitochondrial function decreases with age [222] and is associated with both a decrease in mtDNA 
content and an increase in oxidative mtDNA damage [223]. As a result, mtDNA damage is linked to 
numerous age-related conditions [224], including heart failure, Parkinson’s disease, diabetes [225], and 
cancer [226,227]. 
mtDNA is susceptible to damage induced by a variety of agents, including ultraviolet [228] and 
ionizing radiation [229], as well as ROS [127,228,229]. Mambo et al. indentified the D-loop as a 
region of mtDNA that is highly susceptible to oxidative damage compared to other regions [230]. 
Cortopassi  and  Wang  found  that  mtDNA  sequences  that  encode  various  Complex  I  subunits  are 
statistically more susceptible to damage, which may contribute to increased superoxide production and 
age-related diseases [231]. In cells that lack mtDNA (ρ
0 cells) or cells that express mtDNA with a 
common  4977-bp  deletion,  there  is  a  significant  increase  in  ROS  production  compared  to  either 
parental cells or cells in which wild-type mtDNA has been introduced [232], and MnSOD is expressed 
as  an  adaptive  response  to  the  depletion  of  mtDNA  [233].  A  vicious  cycle  is  set  in  motion  in  
which mtDNA damage results in altered mitochondrial function, leading to increased ROS production, 
which  causes  more  mtDNA  damage  [234].  Using  simian  virus  40  (SV40)-transformed  human 
fibroblast  cell  line  GM00637E,  Yakes  and  van  Houten  found  that  mtDNA  is  more  sensitive  to 
oxidative stress-induced damage caused by hydrogen peroxide treatment than nuclear DNA, mtDNA 
damage occurs more rapidly, and during prolonged exposure to hydrogen peroxide (60 min), mtDNA 
damage  was  not  repaired.  mtDNA  damage  in  GM00637E  cells  correlates  with  a  decrease  in 
mitochondrial function as measured by MTT reduction [235]. Hydrogen peroxide is identified as an 
important mediator of oxidative mtDNA damage induced by UV irradiation [228].  
Polγ is susceptible to oxidative stress-mediated inactivation, which may affect mtDNA replication 
and repair. For example, Graziewicz et al. found that treatment of the catalytic subunit of Polγ with 
hydrogen peroxide causes oxidative modification of the protein and results in an approximately 50% 
reduction in polymerase activity in a time- and dose-dependent manner, as well as a decrease in Polγ 
DNA binding activity. Polγ is more sensitive to oxidative inactivation than Polβ and Polα, two nuclear 
DNA polymerases.  
MnSOD plays an important role in protecting mtDNA from ROS-induced damage. Steinman et al. 
found that MnSOD associates with DNA in Escherichia coli K-12 cells [236]. Oxidative mtDNA 
damage  increases  with  age  in  mice,  but  this  damage  is  much  greater  in  the  livers  of  MnSOD 
heterozygous knockout mice compared to wild-type controls [103]. MnSOD expression is increased in 
peripheral blood mononuclear cells from type 2 diabetic patients as an adaptive response to increased 
oxidative mtDNA damage in these cells [237]. In bovine retina endothelial cells, overexpression of 
MnSOD  or  treatment  with  a  MnSOD  mimetic  inhibits  oxidative  mtDNA  damage  caused  by  high 
glucose, resulting in an increase in the expression of various electron  transport chain  components 
compared to cells treated with glucose alone [238]. Overexpression of MnSOD also protects mtDNA 
from oxidative damage induced by exposure to UV radiation [228], as well as mtDNA damage and 
depletion caused by acute ethanol exposure [129,239]. MnSOD has been identified  as part of  the 
nucleoid complex, where it interacts with mtDNA, Polγ, and glutathione peroxidase and may play a 
role  in  protecting  mtDNA  from  oxidative  stress-induced  damage  [240].  Work  by  this  laboratory 
confirmed  that  MnSOD  interacts  with  Polγ  and  mtDNA,  and  demonstrated  that  MnSOD  may  be Int. J. Mol. Sci. 2011, 12                       
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important for protecting mtDNA from UV-induced damage by preventing inactivation of Polγ [241]. 
These studies suggest a potential role for MnSOD in the prevention or treatment of diseases associated 
with mtDNA damage. 
4.7. Cellular Lipid Integrity 
Lipids, especially polyunsaturated lipids, are susceptible to attack by ROS. A variety of compounds 
resulting from lipid peroxidation have been identified, such as 4-hydroxynonenal and malondialdehyde, 
as  well  as  products  derived  from  the  oxidative  attack  of  cholesterol,  cholesterol  esters,  and 
sphingholipids [242]. Lipids are also vulnerable to attack by RNS to form different oxidation and 
nitration products [243–246], and these RNS-derived lipid peroxidation products may have importance 
in such diverse functions as inflammation [243] and ischemia/reperfusion injury [247].  
Altered  MnSOD  expression  or  activity  can  also  have  consequences  on  total  cellular,  and 
mitochondrial,  lipid  integrity.  Heterozygous  MnSOD  knockout  mice  have  substantially  more  lipid 
peroxidation  (as  determined  by  immunohistological  staining  for  8-isoprostane,  a  marker  of  lipid 
peroxidation)  at  day  10  after  birth  compared  to  wild-type  counterparts  [248].  On  the  contrary, 
overexpression of MnSOD in the PC6 pheochromocytoma cell line attenuates lipid peroxidation and 
the formation 4-HNE-adducted proteins caused by treatment with Fe(II), sodium nitroprusside (a nitric 
oxide-generating agent), and amyloid β-peptide, as well as lipid peroxidation in vivo caused by local 
cerebral ischemia [188]. Administration of MnSOD plasmid/liposome intraesophageally or intraorally 
into mice to induce localized overexpression of MnSOD protects the animals from lipid peroxidation 
induced by ionizing radiation compared to control mice [249].MnSOD may also play a role in lipid 
peroxidation caused by hypertension. Using normotensive rats and either spontaneously hypertensive or 
induced hypertensive rats, Ohtsuki et al. discovered that lipid peroxidation in enriched mitochondrial 
fractions of brain tissue was greater with age in spontaneously hypertensive and deoxycorticosterone 
acetate  (DOCA)-induced  hypertensive  rats  compared  to  normotensive  or  vehicle-treated  rats, 
respectively. No significant changes in mitochondrial lipid peroxidation were observed in either heart 
or kidney tissue. MnSOD expression increased with age only in the normotensive rats in brain tissue. 
These  results  suggest  that  altered  superoxide  radical  metabolism  may  contribute  to  neurological 
conditions associated with hypertension [250]. 
Since MnSOD contains manganese in its active site [85], factors that affect manganese availability 
can  also  have  a  marked  effect  on  lipid  peroxidation.  Manganese  deficiency  significantly  reduces  
age-related increases in MnSOD activity compared to manganese-sufficient rats, correlating with a  
5-fold increase in lipid peroxidation in manganese-deficient rat liver compared to a 3-fold increase in 
rats receiving adequate amounts of manganese [251]. Malecki and Greger found that lipid peroxidation 
was greater in rat heart mitochondria in animals deficient in Mn compared to rats receiving adequate 
amounts of manganese, which inversely correlated with MnSOD activity [252]. Manganese deficiency 
has been identified in patients with sundry diseases, including epilepsy [253], diabetes mellitus [254], 
and patients receiving hemodialysis [255]. Future studies of how this manganese deficiency correlates 
with  MnSOD  activity  and  lipid  peroxidation  in  these,  and  other,  diseases  may  provide  important 
insights into mechanisms of disease development.  Int. J. Mol. Sci. 2011, 12                       
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Cardiolipin is a tetra-acylated glycerophospholipid composed of two phosphotidyl groups linked  
by glycerol, resulting in a lipid with four hydrocarbon chains and three chiral centers [256] Cardiolipin 
is found almost entirely in the inner mitochondrial membrane [257]. Altered levels and composition  
of  cardiolipin  is  associated  with  various  diseases  involving  mitochondrial  dysfunction,  including 
ischemia/reperfusion injury, diabetes, heart failure [258,259], aging [260,261], and cancer [262–264]. 
Cardiolipin  is  also  linked  to  Barth  syndrome,  an  X-linked  cardiomyopathic  disease  characterized  
by neutropenia, cardiomyopathy, and 3-methylglutaconic aciduria [265]. Barth syndrome is caused,  
in  part,  by  a  mutation  in  tafazzin,  a  phospholipid  acyltransferase  important  for  assembly  of  
cardiolipin [266–268].  
Cardiolipin  is  vital  for  the  proper  function  of  many  mitochondrial  activities.  For  example, 
cardiolipin is important for the initiation of apoptosis [269–275]. Peroxidation of cardiolipin leads to 
the release of cytochrome c from mitochondria [270,276] and opening of the permeability transition 
pore (PTP) by inactivation of the adenine nucleotide translocator (ANT) [270]. Cardiolipin is vital for 
the activities of individual components of the electron transport chain [277] and the assembly of these 
components into supramolecular complexes [278,279]. Cardiolipin is susceptible to peroxidation by 
ROS [261,280,281], and ROS-mediated inactivation of different complexes of the electron transport 
chain parallel oxidative damage of cardiolipin. Treatment with a combination of SOD and catalase, or 
supplementation with exogenous cardiolipin, reverses the effects of ROS on electron transport chain 
components and cardiolipin peroxidation [282–286]. In HaCaT human keratinocytes, low dose UVB 
radiation  leads  to  decreased  activities  of  different  electron  transport  chain  components  with  a 
concurrent decrease in cardiolipin content. MnSOD protein levels increase after UVB exposure as an 
adaptive response to UVB exposure [287]. These studies imply a potential mechanism for MnSOD in 
protecting mitochondria from ROS-induced damage by preventing cardiolipin peroxidation. 
5. Implications for Disease 
5.1. Cancer 
ROS are important for the development of cancer by many mechanisms, including ROS-mediated 
DNA damage, activation of various transcription factors, and initiation of multiple signal transduction 
pathways  [288–290].  MnSOD  seems  to  play  a  dual  role  in  cancer  development  and  progression 
(recently reviewed in [291]). Some studies show elevated MnSOD expression in cancer compared to 
normal tissue [292–298], while other studies show MnSOD is reduced in many types of cancer [28], 
including breast cancer [299,300], pancreatic cancer [301], and ovarian cancer [302]. Depending on the 
type of cancer and its stage of development, MnSOD may act as either a tumor suppressor or a tumor 
promoter. For example, MnSOD expression is associated with an increase in lymph node metastases of 
both  colorectal  [303]  and  gastric  cancer  [292],  and  is  important  for  the  metastatic  behavior  of  the 
estrogen-independent breast cancer cell line MDA-MB-231 [304], as well as progestin-stimulation of 
migration and invasion in T47D human breast cancer cells [305]. One mechanism of MnSOD-enhanced 
metastasis is stimulation of matrix metalloproteinase expression through hydrogen peroxide-dependent 
mechanisms [306,307]. On the other hand, other studies have demonstrated that overexpression of Int. J. Mol. Sci. 2011, 12                       
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MnSOD  inhibits  many  of  the  hallmark  properties  of  cancer,  such  as  increased  growth  rate, 
invasiveness, and anchorage independent cell growth [300,308–311].  
Alteration of ROS levels induced by chemical carcinogens is important for the tumor suppressive 
effects of MnSOD [312–314]. Overexpression of MnSOD sensitizes cancer cells to cell death induced 
by various ROS-generating  agents both in  vitro  and in  vivo [315].  In  HEK293 human embryonic 
kidney  cells,  overexpression  of  an  active  site  mutant  of  MnSOD  lacking  product  inhibition  
causes ROS-mediated growth retardation, which was abrogated by co-expression of catalase [316]. 
Ridnour et al. discovered that MnSOD overexpression in XR23M transformed x-ray immortalized rat 
embryo  fibroblast  cells  decreases  the  tumorigenicity  of  these  cells  (decreased  colony  formation, 
diminished tumor growth in vivo, and diminution of metastatic potential) in a manner that correlates 
with  MnSOD-mediated  production  of  hydrogen  peroxide  [312].  MnSOD  overexpression  in  PC-3 
human prostate cancer cells have higher levels of hydrogen peroxide and mitochondrial membrane 
potential compared to parental cells, correlating with decreased cell growth [309]. 
A major concentration of study for this laboratory has been to refine the importance of MnSOD in 
oxidative stress-induced tumor initiation and promotion. In the Fsa-II mouse fibrosarcoma cell line, 
MnSOD overexpression decreases proliferation and colony formation with a simultaneous induction  
of differentiation, in part by inhibiting AP-1 DNA binding activity and expression of AP-1 target  
genes  [317].  MnSOD  overexpression  both  inhibits  5-azacytidine-induced  apoptosis  and  enhances 
differentiation in Fsa-II cells by activation of NF-κB and the ERK MAP kinase pathway [318]. Using 
the DMBA (7,12-dimethylbenz[a]-anthracene)/TPA (12-O-tetradecanoylphorbol-13-acetate) treatment 
regimen  for  tumor  initiation  and  promotion,  this  laboratory  found  that  overexpression  of  MnSOD 
reduces  the  incidence  and  number  of  papillomas  per  animal  compared  to  non-transgenic  mice  by 
inhibiting TPA-induced oxidative stress [319]. 
Based on the results in MnSOD overexpressing mice, it seems logical that knockdown of MnSOD 
would enhance DMBA/TPA-induced tumorigenesis. DMBA/TPA treatment of heterozygous knockout 
of MnSOD in the C57BL/6 mouse model resulted in a similar number of papillomas as wildtype mice. 
The similarity in papilloma formation between the two genotypes results from an increase in both 
proliferation and apoptosis in the basal layer of the epidermis. A major difference between the MnSOD 
knockout and wildtype mice is an increase in oxidative stress, signified by an increase in oxidized 
proteins [320]. It was later revealed that apoptosis precedes proliferation in the basal layer of the 
epidermis. Apoptosis peaks at 6 h post-TPA treatment, while mitosis peaks 24 h after treatment, and 
proliferation is less in wildtype mice than MnSOD knockout animals. When mice were treated with the 
MnSOD mimetic MnTE-2-PyP5+ 12 h subsequent to each TPA treatment, no effect on apoptosis was 
observed, but a significant reduction in TPA-stimulated proliferation and oxidative modification of 
proteins occurred, resulting in a 50% reduction in tumor incidence compared to DMBA/TPA treatment 
alone. These results suggest that oxidative stress is an important event early in tumorigenesis and 
provide a potential mechanism by which MnSOD inhibits cancer formation [321]. 
Another  area  of  research  for  MnSOD  in  cancer  development  is  the  effect  of  single  nucleotide 
polymorphisms (SNPs) in the SOD2 gene that alter the overall expression, function, or subcellular 
localization of MnSOD. One such polymorphism, resulting in a C→T transition, causes the conversion 
of valine to alanine at amino acid 16 in the mitochondrial signaling sequence of MnSOD [322]. The 
Ala16 variant can easily enter the matrix and has higher activity than the Val16 variant, which remains Int. J. Mol. Sci. 2011, 12                       
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embedded in the inner membrane. Differences in the secondary structure of the two variants explain 
the difference in mitochondrial migration. The Ala16 variant has a partial α-helical structure, while the 
Val16 variant adopts  a  β-sheet structure.  The structural differences between the Ala16 and Val16 
variants of MnSOD affect the interaction of the protein with the Tim23 import channel in the inner 
mitochondrial  membrane,  which  affect  localization  of  MnSOD  within  the  matrix  and  subsequent 
activity [323,324].  
The  specific  role  of  the  Val16Ala  SNP  in  cancer  development  remains  controversial  [325].  
Some studies suggest a link between the Val16Ala SNP and risk of ovarian cancer [326,327] and lung 
cancer [328]. Individuals with the Val/Val genotype have a significantly greater risk of lung cancer 
compared to those with the Ala/Ala genotype [329,330]. The Val/Val and Val/Ala genotypes increase 
lung cancer risk in an age-dependent manner, with patients younger than 55 years carrying either the 
Val/Val  or  Val/Ala  genotype  having  a  greater  risk  than  older  patients  [330].  The  opposite  trend 
appears  with  prostate  cancer.  Men  that  are  homozygous  for  the  Ala  polymorphism  have  a  70% 
increased prostate cancer risk than men homozygous for the Val polymorphism [331], and there is an 
increased risk for early-onset prostate cancer (≤65 years) in men that are homozygous or heterozygous 
for the Ala polymorphism compared to Val homozygous men [332].  
Many other polymorphisms have been identified in the SOD2 gene. Ile58 is an important amino 
acid  that  lies  at  the  tetrameric  interface  of  the  four  monomers  that  comprise  mature  MnSOD  
protein [81]. The Ile58Thr polymorphism (rs1141718) causes destabilization of the tetrameric interface 
and formation of primarily dimeric MnSOD. The thermal sensitivity of MnSOD is also increased with 
the Ile58Thr polymorphism. Borgstahl et al. found that Thr58 variant of MnSOD had about half of the 
enzyme activity as the normal protein at all temperatures tested [333]. The diminished enzyme activity 
of the Thr58 variant of MnSOD reduces its tumor suppressor activity in MCF-7 human breast cancer 
cells compared to the Ile58 variant [334]. Other polymorphisms of MnSOD that have been identified 
include Leu60Phe (rs11575993) [335] and G1677T (rs2Y758Y339) [336]. Leu60Phe is observed in 
the Jurkat human T-cell leukemia cell line, resulting in reduced MnSOD enzyme activity in Jurkat 
cells compared to normal human peripheral blood lymphocytes [335]. The G1677T polymorphism 
generates a potential glucocorticoid receptor binding site near the enhancer localized within the second 
intron of the SOD2 gene. The T/T genotype correlates with a reduction in the risk of lung cancer [336].  
MnSOD polymorphisms, while affecting cancer incidence, may also have an effect on response to 
treatment. Using patient populations from the United States and Norway, Glynn et al. found that patients 
with the Ala allele for the Val16Ala SNP, and were receiving cyclophosphamide chemotherapy regimens 
had a significant reduction in survival compared to patients with the Val allele [337]. Yao et al. studied 
the effects of the Val16Ala MnSOD polymorphism on treatment-induced hematological toxicity and 
disease-free survival using data from a Southwest Oncology Group (SWOG) clinical trial (S8897). 
Breast  cancer  patients  receiving  adjuvant  therapy  (either  the  combination  of  cyclophosphamide, 
doxorubicin,  and  5-fluorouracil  or  the  combination  of  cyclophosphamide,  methotrexate,  and  
5-fluorouracil)  that  were  homozygous  for  cytosine  allele  and  the  Val16Ala  polymorphism  had  a 
significant reduction in the risk of developing grade 3 and 4 neutropenia than women homozygous for 
the thymidine allele. The homozygous cytosine allele group also had a non-significant reduced risk of 
developing grade 3 and 4 leucopenia. Interestingly, women that were heterozygous for the cytosine 
allele had a non-significant increased risk of disease recurrence or death [338]. These results suggest a Int. J. Mol. Sci. 2011, 12                       
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need for genotyping patients for MnSOD SNPs to tailor the cancer chemotherapy regime to improve 
patient survival and to minimize side effects. 
One of the hallmarks of cancer is the referred to as the Warburg effect, a process by which cancer 
cells  switch  from  oxidative  phosphorylation  for  ATP  production  to  glycolysis-dependent  ATP 
production, even at high levels of oxygen [339], due to dysfunctional oxidative phosphorylation in 
mitochondria caused by various mechanisms, including damage to mtDNA and nuclear DNA that 
encodes various genes for oxidative phosphorylation [340,341]. Genes encoding various enzymes in 
the glycolysis pathway are overexpressed in numerous cancer types [342]. The switch to glycolysis 
gives  cancer  cells  several  advantages,  including  the  production  of  various  substrates  essential  for 
proliferation [343] and protection from ROS-mediated apoptosis [344]. Since cancer cells develop a 
“sweet tooth” for glucose, various strategies targeting the glycolysis pathway have been developed to 
treat cancer [343,345].  
Sirtuin 3 (SIRT3) is a NAD
+-dependent deacetylase localized to mitochondria [346]. SIRT3 is an 
important tumor suppressor that helps to preserve mitochondrial integrity, inhibits mitochondrial ROS 
production, and hinders the Warburg effect by suppressing ROS-dependent stabilization of HIF-1α and 
expression  of  HIF-1α  target  genes  [347–349].  MnSOD  can  undergo  various  post-translational 
modifications that alters MnSOD enzyme  activity  (reviewed in [350]). MnSOD has  recently  been 
identified as a SIRT3 target, with SIRT3-dependent deacetylation of MnSOD at Lys122 being vital for 
maintaining MnSOD in an active state [351], and regulation of MnSOD activity by SIRT3 may be 
important in the cellular response to nutrient status and various types of stress (reviewed in [352]). 
Because  of  the  importance  of  MnSOD  in  protecting  different  mitochondria-centered  metabolic 
enzymes from ROS-mediated deactivation, the decrease in MnSOD expression and activity associated 
with cancer, and the fact MnSOD is a target of SIRT3 deacetylase, it is tempting to speculate that 
MnSOD may be essential for initiation of the Warburg effect in the development and progression of 
cancer. Future work may need to be focused on the link between MnSOD and the Warburg effect. 
Other work may  also be concentrated on which comes first, decreased MnSOD expression or the 
Warburg  effect,  and  whether  a  feedback  mechanism  exists  between  MnSOD-dependent  ROS 
detoxification and the metabolic switch to glycolysis.  
5.2. Cardiovascular Disease 
Altered  expression  of  MnSOD  is  observed  in  various  cardiovascular  disorders.  In  ventricular 
myocardium from heart failure patients, there is a significant increase in superoxide production, as 
determined by electron paramagnetic resonance, compared to non-failing heart tissue. While MnSOD 
mRNA levels are elevated in failing myocardium, there is a decrease in protein levels and enzyme 
activity  compared  to  non-failing  heart,  suggesting  that  some  post-transcriptional  regulation  or  
post-translational  modification  of  MnSOD  occurs  to  prevent  a  complete  adaptive  response  to  the 
increased  superoxide  levels  [353].  Myocardial  infarction  in  rat  heart  causes  a  region-specific 
expression of MnSOD. The left ventricle shows an early increase in MnSOD mRNA levels at 6 h  
post-infarction, peaks at 12 h, then declines at 48 h. On the other hand, the right ventricle shows a 
steady increase in MnSOD mRNA up to 48 h. The increase in MnSOD mRNA does not lead, however, 
to  a  corresponding  increase  in  enzyme  activity  [354].  Csonka  et  al.  found  that  expression  of Int. J. Mol. Sci. 2011, 12                       
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glutathione peroxidase, CuZnSOD, and MnSOD are elevated in spontaneously hypertensive (SH) rats 
compared to controls, and this elevation in antioxidant capacity protects the SH  rats  from further 
oxidative stress caused by infusion of hydrogen peroxide [355]. Khaper et al. followed the expression 
of various antioxidant enzymes, including MnSOD, at different times following myocardial infarction 
in rats, and found that MnSOD mRNA levels were reduced early (1 week) and long after (16 weeks) 
infarction, but MnSOD mRNA was near control levels at 4 weeks post-infarction [356]. 
MnSOD knockout animal models have proven valuable in determining the mechanisms underlying 
changes  in  cardiac  function  with  variations  in  MnSOD  expression.  Using  a  mouse  model  with 
tetracycline-dependent expression of MnSOD, Loch et al. found that loss of MnSOD results in reduced 
left ventricular function (decreased fraction shortening and ejection fraction, increased left ventricular 
diameter at systole). These mice also developed heart hypertrophy [357]. Reduced MnSOD levels also 
increase the sensitivity  of cardiomyocytes to mitochondria-centered apoptosis induced by different 
agents [358]. MnSOD is also important for blood pressure regulation. Decreased expression of MnSOD 
in various mouse models results in impaired vasorelaxation [359,360] and greater vasoconstriction [360] 
induced  by  various  agents  in  old  animals  compared  to  young  animals,  which  show  no  significant 
differences in responses. 
Not only are polymorphisms of the MnSOD gene important for cancer development, they also have 
an impact on cardiovascular disease. Kakko et al. found that the Val16 polymorphism of mitochondrial 
signaling  sequence  of  MnSOD  was  a  minor  component  explaining  differences  in  intima-media 
thickness (a measure of carotic atherosclerosis) between subjects [361]. The Val/Val genotype is an 
independent  risk  factor  for  coronary  artery  disease  (CAD)  and  the  frequency  of  this  allele  is 
significantly higher in CAD patients that had an acute myocardial infarction [362], and is also higher 
in patients with vasospastic angina compared to healthy subjects [363]. 
MnSOD is vital for protecting cardiac tissue from damage caused by various factors. Miller et al. 
identified MnSOD as an important component in protecting endothelial cells from cyclooxygenase-1 
(COX-1)-mediated dysfunction [364]. Negoro et al. identified MnSOD as a STAT3 (signal transducer 
and activator of transcription 3) target gene vital for STAT3-mediated protection of cardiac tissue from 
hypoxia/reoxygenation-induced injury [365]. Jin et al. discovered that after ischemia/reperfusion of 
mouse heart, there is a significant increase in cytosolic MnSOD and release of cytochrome c from 
mitochondria, which was prevented by ischemic preconditioning or treatment with the mitochondria 
permeability transition pore inhibitor cyclosporin A [366]. 
Nitration  is  an  important  post-translational  modification  of  MnSOD  that  can  alter  the  cellular 
response  to  normal  and  stress-induced  conditions.  MacMillan-Crow  et  al.  identified  MnSOD  as  a 
protein  nitrated  in  chronically  rejected  kidney  transplants,  correlating  with  a  decrease  in  MnSOD 
enzyme  activity  in  these  transplanted  organs.  Exposure  of  recombinant  MnSOD  to  peroxynitrite  
in  vitro  results  in  a  statistically  significant  decrease  in  MnSOD  enzyme  activity,  confirming  the 
importance of nitration in modulating MnSOD activity [367]. The site of nitration on MnSOD was 
later  identified  as  Tyr34  [368,369],  which  is  found  in  the  active  site  on  MnSOD.  X-ray 
crystallographic studies of both the unmodified and Tyr34-nitrated MnSOD reveal that nitration at 
Tyr34 can weaken the hydrogen bonding of the active site, which may affect proton transfer during 
dismutation of superoxide, as well as impede substrate access and binding to the active site [370].  Int. J. Mol. Sci. 2011, 12                       
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MnSOD nitration can have significant effects on cardiovascular disease development and progression 
caused  by  therapeutic  agents.  Xu  et  al.  identified  Tyr34-nitrated  MnSOD  in  atherosclerotic  cardiac 
atrium from diabetic patients [371]. Cyclosporine A (CsA), while an important immunosuppressant used 
in  organ  transplant  patients,  also  has  significant  side  effects,  including  cardiovascular  injury  [372]. 
Oxidative stress appears to be a component of CsA-mediated injury [373]. CsA stimulates peroxynitrite 
production and subsequent nitration of many proteins in both aortic endothelium and bovine aortic 
endothelial  cells,  including  MnSOD  [374].  Cyclosporine  A-induced  nitration  and  inactivation  of 
MnSOD is dependent, in part, on endothelial nitric oxide synthase (eNOS)-dependent production of 
nitric oxide and mitochondrial superoxide [375].  
5.3. Neurological Disorders 
Not only does MnSOD expression affect cardiovascular disease, but it also appears to have crucial 
consequences  on  neurodegenerative  disorders,  including  ischemia/reperfusion  injury  caused  by  
stroke [376], sleep apnea-induced chronic intermittent hypoxia [377], HIV-associated dementia [378], 
and neurological dysfunction resulting from traumatic brain injury [379,380]. In cultured neuronal 
cells, MnSOD transfection prevents iron- and β-amyloid-induced cell death [188], while knockdown of 
MnSOD  augments  glutamate-induced  toxicity  in  mouse  cortical  neurons  [381].  Overexpression  of 
MnSOD  protects  cortical  cultures  from  N-methyl-D-aspartate  (NMDA)  and  nitric  oxide-induced 
toxicity [382], as well as decreases lesion volume after traumatic brain injury compared to wildtype 
mouse littermates [383]. Homozygous knockout mice have death of neurons in both the basal ganglia 
and the brain stem and show severe mitochondrial damage [106]. In Sod2
−/− B6D2F1 mice, ataxia 
develops by postnatal day 11 (P11) and frequent seizures occur by P14, which are associated with 
damage to the thalamus, motor cortex, and the brain stem (olivary nucleus, vestibular nucleus, motor 
trigeminal nucleus, and mesencephalic trigeminal nucleus) at P11–13, which becomes more extensive 
by P15–16. Vacuole formation occurs in the pyramidal layer of the hippocampus, different regions of 
the thalamus and brain stem, as well as the deeper layers of the motor cortex [384]. Vacuole formation 
is also observed in the brain of a Drosophila model with reduced MnSOD expression, resulting in 
neuronal apoptosis and a diminution of normal olfactory behavior [102]. 
MnSOD appears to be important for the development and progression of Alzheimer’s disease (AD). 
In AD patients, there is a significant increase in MnSOD expression in the C1, CA2/3, and C4 regions 
of the hippocampus compared to non-AD patients. These results suggest that MnSOD expression is 
part  of  a  compensatory  mechanism  in  the  hippocampus  for  the  increase  in  ROS  linked  to  AD 
progression [385]. MnSOD overexpression in the Tg19959 mouse model of  AD has no  effect on 
amyloid precursor protein expression or processing, but does cause a significant decrease in amyloid 
plaque  burden  in  the  cortex  and  a  nonsignificant  decrease  of  plaques  in  the  hippocampus  and  a 
decrease in cortical microglia. These mice also show improved spatial memory retention [386]. On the 
other hand, heterozygous knock-out of MnSOD in T19959 mice increases the oxidative damage to 
various  brain  proteins  and  results  in  a  significant  increase  in  plaque  burden  in  the  hippocampus, 
retrospenial/motor cortex, and cortex [387]. 
Much  work  by  this  laboratory  has  focused  on  the  role  of  MnSOD  in  the  development  and 
progression of AD. Using isolated primary neurons from wild-type or amyloid precursor protein (APP) Int. J. Mol. Sci. 2011, 12                       
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and presenilin (PS1) double knock-in (APP/PS1) mice, Sompol et al. discovered that mature APP/PS1 
neurons have decreased MnSOD expression and an increase in the colocalization of nitrotyrosine with 
MnSOD,  suggesting  that  MnSOD  enzyme  activity  may  be  inhibited  by  tyrosine  nitration  [388]. 
Increased  MnSOD  nitration  was  observed  in  APP/PS1  mice  compared  to  wild-type  controls, 
correlating with both a decrease in MnSOD enzyme activity and reduced mitochondrial activity [389], 
suggesting that tyrosine nitration of MnSOD may be an important component of neuronal injury in AD.  
The interaction of MnSOD with various proteins can have dramatic effects on MnSOD activity and, 
ultimately,  on  global  cellular  homeostasis.  Eldridge  et  al.  used  a  gel-based  mass  spectrometry 
technique for identifying proteins that interact with MnSOD that enhance MnSOD enzyme activity 
during adaptive radioresistance. These proteins are involved in such diverse functions as DNA repair, 
apoptosis, cell cycle regulation, and mitochondrial function [390]. The cell cycle regulators cyclin D1 
and cdk4 have been identified as proteins that directly interact with MnSOD. This interaction may be 
important for the  regulation of mitochondrial function during low dose  radiation-induced adaptive 
response  [391].  Studies  like  this  may  provide  important  insights  into  proteins  that  interact  with 
MnSOD and the role of these interactions in regulating mitochondrial function, in particular, and the 
overall affect of these interactions on global cellular function and disease development. 
Off-target  effects  of  chemotherapeutic  drugs  are  a  major  research  area  for  this  laboratory,  and 
recent  work  in  this  laboratory  demonstrates  the  importance  of  MnSOD/protein  interactions.  One  
such avenue of study is the cognitive decline associated with different chemotherapy regimens referred 
to as “chemobrain” (see Effects of MnSOD on Mitochondrial Integrity/Function above). Using the  
SK-N-SH  human  neuroblastoma  cell  line,  this  laboratory  showed  that  treatment  with  the  cancer 
chemotherapy drug paclitaxel (PTX) causes an increase in MnSOD expression with no corresponding 
increase in MnSOD enzyme activity, which correlated with an increase in mitochondrial localization 
of p53. p53 interacts directly with MnSOD, and chemical inhibition of PTX-induced mitochondrial 
translocation  of  p53  using  pifithrin-µ  partially  rescues  MnSOD  enzyme  activity  from  inhibition 
induced by PTX. These results suggest that inhibition of MnSOD enzyme activity by direct interaction 
of MnSOD with p53 may be an important mechanism of PTX-induced neurotoxicity [392].  
Parkinson’s  disease  (PD)  is  a  progressive  neurodegenerative  disorder  marked  by  the  loss  of 
dopaminergic neurons in the substantia nigra, basal nuclei, and the tectum mesencephalicum, as well 
as  the  formation  of  eosinophilic  fibrillary  intracellular  inclusions  in  neurons  referred  to  as  Lewy  
bodies  [393].  Altered  mitochondrial  function  and  dynamics  are  important  characteristics  for  the 
progression  of  PD  and  have  been  linked  to  several  PD-specific  genes  [394–396].  Mitochondrial  
ROS are a key component to PD development [397], with complex I of the electron transport chain 
acting as both a victim, and source, of ROS [122,125,397]. Several studies demonstrate that while 
polymorphisms of the MnSOD gene associated with other diseases, namely the Val16Ala and Ile58Thr 
polymorphisms, are not associated with PD risk [398–400], the Val16Ala polymorphism is linked to 
PD resulting from exposure to pesticides [398].  In a study using MPTP (1-methyl-4-phenyl-1,2,3, 
6-tetrahydropyridine), 3-nitropropionic acid (3-NP), and malonate to induce PD symptoms in mice, 
Andreassen et al. found that heterozygous MnSOD knockout mice have greater dopamine depletion 
and  larger  striatal  lesions  compared  to  wildtype  mice  [401].  Liang  and  Patel  found  that  MPTP 
treatment results in aconitase inactivation in a time-dependent manner, correlating with an increase in Int. J. Mol. Sci. 2011, 12                       
 
 
7135 
chelatable iron. These effects were assuaged in mice overexpressing MnSOD, providing further evidence 
that MnSOD expression is an essential factor in PD resulting from environmental toxicants [402].  
6. Conclusions 
Mitochondria play a central role in numerous metabolic pathways in the cell, with functions as 
diverse as ATP production through oxidative phosphorylation to iron metabolism and utilization. ROS 
derived  from  mitochondria  can  have  injurious  effects  on  enzymes  involved  in  these  metabolic 
pathways  and  other  functions  of  mitochondria,  leading  to  mitochondrial  dysfunction  and  cellular 
injury/death, culminating in disease development (Figure 1). The mitochondrial antioxidant enzyme 
MnSOD scavenges superoxide radicals produced within the organelle and can protect mitochondria 
from the harmful effects of ROS. Methods to increase the expression or activity of MnSOD may prove 
to  be  valuable  strategies  for  the  treatment  of  various  disease  conditions  involving  aberrant 
mitochondrial ROS production, including numerous neurological conditions, cardiovascular disease, 
and cancer that plague countless individuals worldwide. 
Figure  1.  Mitochondria  are  the  major  source  of  ROS  in  the  cell  through  superoxide 
production at complexes I and III of the electron transport chain (center). Excessive ROS 
production  can  damage  different  components  of  mitochondrial  metabolic  pathways, 
resulting  in  altered  mitochondrial  function  and  an  imbalance  in  cellular  homeostasis  
(inner  ring).  Diminished  mitochondrial  function  leads  to  the  development  of  numerous 
diseases (outer ring). 
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